{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:58:03Z","timestamp":1783648683930,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006393","name":"Universidad de Granada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006393","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.biopha.2021.112069","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T13:44:02Z","timestamp":1630158242000},"page":"112069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Pharmacogenetic polymorphisms affecting bisoprolol response"],"prefix":"10.1016","volume":"142","author":[{"given":"Celia","family":"Casta\u00f1o-Amores","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xando","family":"D\u00edaz-Villamar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"P\u00e9rez-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Ant\u00fanez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pozo-Agundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Moreno-Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas Gabriel","family":"S\u00e1nchez-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Javier","family":"Mart\u00ednez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Luc\u00eda","family":"D\u00e1vila-Fajardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.112069_bib1","unstructured":"(AEMPS) AEdMyPS. Drug label: Emconcor 2020, Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/63046\/FT_63046.html."},{"issue":"2","key":"10.1016\/j.biopha.2021.112069_bib2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1755-5922.2011.00306.x","article-title":"Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity","volume":"31","author":"Ladage","year":"2013","journal-title":"Cardiovasc Ther."},{"issue":"8","key":"10.1016\/j.biopha.2021.112069_bib3","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1177\/2047487318825350","article-title":"Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry","volume":"26","author":"Kotseva","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"8","key":"10.1016\/j.biopha.2021.112069_bib4","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1177\/2047487314547652","article-title":"Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: Data from the contemporary CLARIFY registry","volume":"22","author":"Ferrari","year":"2015","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"12","key":"10.1016\/j.biopha.2021.112069_bib5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/clc.20981","article-title":"Differential effect of \u03b2-blockers for heart rate control in coronary artery disease","volume":"34","author":"Cordero","year":"2011","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.biopha.2021.112069_bib6","series-title":"Beta-Blockers Utilization in Heart Failure Patients: Sub-analysis of a Nation-wide Population-Based Study in the Czech Republic","author":"Taborsky","year":"2020"},{"issue":"3","key":"10.1016\/j.biopha.2021.112069_bib7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1021\/js970316d","article-title":"Pharmacokinetics and metabolism of bisoprolol enantiomers in humans","volume":"87","author":"Horikiri","year":"1998","journal-title":"J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2021.112069_bib8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.recesp.2019.02.024","article-title":"Role of beta-blockers in cardiovascular disease in 2019","volume":"72","author":"Mart\u00ednez-Milla","year":"2019","journal-title":"Rev. Esp. Cardiol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112069_bib9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.pharmthera.2011.11.002","article-title":"Cardiovascular pharmacogenetics","volume":"133","author":"Myburgh","year":"2012","journal-title":"Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.biopha.2021.112069_bib10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2021.112069_bib11","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1592\/phco.27.6.874","article-title":"Pharmacogenetics of beta-blockers","volume":"27","author":"Shin","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.biopha.2021.112069_bib12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10741-008-9094-x","article-title":"Beta-blocker pharmacogenetics in heart failure","volume":"15","author":"Shin","year":"2010","journal-title":"Heart Fail. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2021.112069_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2007.07.002","article-title":"Beta-1 and beta-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses","volume":"117","author":"Brodde","year":"2008","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2021.112069_bib14","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1161\/STROKEAHA.116.015936","article-title":"Pharmacogenetic associations of \u03b21-adrenergic receptor polymorphisms with cardiovascular outcomes in the sps3 trial (secondary prevention of small subcortical strokes)","volume":"48","author":"Magvanjav","year":"2017","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.biopha.2021.112069_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0009-9236(03)00068-7","article-title":"Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol","volume":"74","author":"Johnson","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2021.112069_bib16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/FPC.0b013e328338e1b8","article-title":"Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment","volume":"20","author":"Suonsyrj\u00e4","year":"2010","journal-title":"Pharm. Genom."},{"issue":"5","key":"10.1016\/j.biopha.2021.112069_bib17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00210-007-0166-6","article-title":"In patients chronically treated with metoprolol, the demand of inotropic catecholamine support after coronary artery bypass grafting is determined by the Arg389Gly-beta 1-adrenoceptor polymorphism","volume":"375","author":"Leineweber","year":"2007","journal-title":"Naunyn-Schmiede 'S. Arch. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112069_bib18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/01213011-200504000-00006","article-title":"Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy","volume":"15","author":"Terra","year":"2005","journal-title":"Pharm. Genom."},{"issue":"1","key":"10.1016\/j.biopha.2021.112069_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jacc.2011.08.061","article-title":"A common \u03b21-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation","volume":"59","author":"Parvez","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112069_bib20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1388-9842(03)00044-8","article-title":"An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study","volume":"5","author":"White","year":"2003","journal-title":"Eur. J. Heart Fail"},{"issue":"1","key":"10.1016\/j.biopha.2021.112069_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.anes.0000267530.62344.a4","volume":"107","author":"Zaugg","year":"2007","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.biopha.2021.112069_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/clpt.2012.18","article-title":"Impact of the \u03b21-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients","volume":"92","author":"Rau","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2021.112069_bib23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/01213011-200503000-00001","article-title":"Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure","volume":"15","author":"de Groote","year":"2005","journal-title":"Pharm. Genom."},{"issue":"1","key":"10.1016\/j.biopha.2021.112069_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10557-010-6220-5","article-title":"Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure","volume":"24","author":"Metra","year":"2010","journal-title":"Cardiovasc Drugs Ther."},{"issue":"7","key":"10.1016\/j.biopha.2021.112069_bib25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00008571-200307000-00002","article-title":"Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure","volume":"13","author":"Kaye","year":"2003","journal-title":"Pharmacogenetics"},{"issue":"11","key":"10.1016\/j.biopha.2021.112069_bib26","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jcph.1443","article-title":"\u03b2(2) -adrenergic receptor gene affects the heart rate response of \u03b2-blockers: evidence from 3 clinical studies","volume":"59","author":"Shahin","year":"2019","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112069_bib27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/jcph.631","article-title":"Pharmacokinetics of metoprolol during pregnancy and lactation","volume":"56","author":"Ryu","year":"2016","journal-title":"J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112069_bib28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/clpt.2008.218","article-title":"Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study","volume":"85","author":"Rau","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2021.112069_bib29","article-title":"Impact of CYP2D6 and ADRB1 polymorphisms on heart rate of post-PCI patients treated with metoprolol","author":"Gao","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.biopha.2021.112069_bib30","first-page":"101","article-title":"Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol. Journal of pharmacy & pharmaceutical sciences: a publication of the Canadian Society for Pharmaceutical Sciences","volume":"9","author":"Takekuma","year":"2006","journal-title":"Soc. Can. Des. Sci. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2021.112069_bib31","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2217\/pgs-2016-0204","article-title":"Replicated evidence for aminoacylase 3 and nephrin gene variations to predict antihypertensive drug responses","volume":"18","author":"Rimpel\u00e4","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.biopha.2021.112069_bib32","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001521","article-title":"Pharmacogenomics of hypertension: a genome\u2010wide, placebo\u2010controlled cross\u2010over study, using four classes of antihypertensive drugs","volume":"4","author":"Hiltunen","year":"2015","journal-title":"J. Am. Heart Assoc."},{"issue":"4","key":"10.1016\/j.biopha.2021.112069_bib33","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4 Suppl 1","key":"10.1016\/j.biopha.2021.112069_bib34","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.amjmed.2007.02.003","article-title":"Variability in response to antihypertensive drugs","volume":"120","author":"Materson","year":"2007","journal-title":"Am. J. Med."},{"key":"10.1016\/j.biopha.2021.112069_bib35","unstructured":"Wells GBS. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011."},{"issue":"7414","key":"10.1016\/j.biopha.2021.112069_bib36","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"issue":"10","key":"10.1016\/j.biopha.2021.112069_bib37","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.sjbs.2020.06.022","article-title":"Bisoprolol responses (PK\/PD) in hypertensive patients: a cytochrome P450 (CYP) 2D6 targeted polymorphism study","volume":"27","author":"Mohammed Alkreathy","year":"2020","journal-title":"Saudi J. Biol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2021.112069_bib38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1515\/dmpt-2018-0015","article-title":"Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking \u03b2-blockers in the Republic of Sakha (YAKUTIA)","volume":"33","author":"Fedorinov","year":"2018","journal-title":"Drug Metab. Pers. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2021.112069_bib39","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3904\/kjim.2015.043","article-title":"Impact of the \u03b2-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between \u03b2 adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study","volume":"31","author":"Lee","year":"2016","journal-title":"Korean J. Intern. Med."},{"issue":"2","key":"10.1016\/j.biopha.2021.112069_bib40","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/ajh.2008.343","article-title":"Renin-angiotensin system and alpha-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: results from the GENRES study","volume":"22","author":"Suonsyrj\u00e4","year":"2009","journal-title":"Am. J. Hypertens."},{"issue":"1","key":"10.1016\/j.biopha.2021.112069_bib41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/hr.2011.166","article-title":"STK39 variation predicts the ambulatory blood pressure response to losartan in hypertensive men","volume":"35","author":"Donner","year":"2012","journal-title":"Hypertens. Res. Off. J. Jpn. Soc. Hypertens."},{"issue":"11","key":"10.1016\/j.biopha.2021.112069_bib42","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.jacc.2005.08.041","article-title":"The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity","volume":"46","author":"Bruck","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112069_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejheart.2003.09.006","article-title":"Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure","volume":"6","author":"de Groote","year":"2004","journal-title":"Eur. J. Heart Fail"},{"issue":"11","key":"10.1016\/j.biopha.2021.112069_bib44","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1097\/HJH.0000000000000714","article-title":"PTPRD gene associated with blood pressure response to atenolol and resistant hypertension","volume":"33","author":"Gong","year":"2015","journal-title":"J. Hypertens."},{"issue":"18","key":"10.1016\/j.biopha.2021.112069_bib45","doi-asserted-by":"crossref","first-page":"12670","DOI":"10.1074\/jbc.274.18.12670","article-title":"A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor","volume":"274","author":"Mason","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"Pt 20","key":"10.1016\/j.biopha.2021.112069_bib46","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1242\/jcs.029223","article-title":"The regulation of salt transport and blood pressure by the WNK-SPAK\/OSR1 signalling pathway","volume":"121","author":"Richardson","year":"2008","journal-title":"J. Cell Sci."},{"issue":"3","key":"10.1016\/j.biopha.2021.112069_bib47","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/HJH.0b013e328342b2c1","article-title":"Serine\/threonine kinase 39 is a candidate gene for primary hypertension especially in women: results from two cohort studies in Swedes","volume":"29","author":"Fava","year":"2011","journal-title":"J. Hypertens."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221008520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221008520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:45:57Z","timestamp":1760100357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221008520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":47,"alternative-id":["S0753332221008520"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112069","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetic polymorphisms affecting bisoprolol response","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112069"}}